Crypto Market Cap, BTC/USD, ETH/USD, USDT/USD, XRP/USD, Bitcoin
Apple, Advanced Micro Devices Inc, Amazon Com Inc, TESLA INC, NETFLIX INC, Facebook Inc
S&P 500, Nasdaq 100, Dow 30, Russell 2000, U.S. Dollar Index, Bitcoin Index
US 10Y, Euro Bund, Germany 10Y, Japan 10Y Yield, UK 10Y, India 10Y
Sellas Life Sciences Group Inc (NASDAQ:SLS) After a solid breakout on rising volume SLS has pulled back to support near $9 and should set up for its next upside move. Things are now beginning to turn in favor of the Bulls. The MACD confirms the recent jump and daily RSI also shows that there's more upside to come. SLS should be watched closely, it could pay off...
Why SELLAS Life Sciences Is Surging Premarket? SELLAS Life Sciences is captivating investors thanks to its late-stage cancer vaccine Thanks to some news in December in the biopharma space, SLS stock is racing higher. So what was that news? And what else do you need to know? its leading candidate Galinpepimut-S is making its way through Phase 3. This...
Looks like we will get some more movement in the next few days. Hope we can hold the support at 5.50 and follow the trendline that was started a month ago before the spike
Great resistance at 7$, with low volume. It looks like it won't go under 7$ again for a while. SLS entered into a share purchase agreement with institutional investors! 7$ per share.Total 16.2 Million $. Once the registered direct offering is closed (yesterday or today? im not sure), I think we will see it at the 10$ level. Institutional investors get in at 7, of...
SLS has been moving between 12 and 11 today. It might be collecting some power for an another spike later today or on Monday. Check the volume and wait for the news later today. My target is near 20$. We will see. Good luck. This is my first post.
Alert set for cross above $3.00 SELLAS Life Sciences Group, Inc. operates as a clinical stage biopharmaceutical company, which focuses on the development and commercialization of novel cancer immunotherapeutics for cancer indications. Its product galinpepimut-S, or GPS, is an immunotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center, or MSK,...
Two catalyst in near future -> Development Pipeline
Increased interest in Friday 15th conference
support area must hold over 0.15 0.16 4h show ngood buy presure for a bounce with rsi 4h trying to push
Will be watching this was a beauty of a morning panic dip buy this morning will be watching key levels today, may dip and bounce for a dead cat bounce
There has not been much good news on this stock lately, but looks like it is trying to make a recovery today. We will be watching this stock for a possible continuation trade tomorrow.
this is what I would prefer to see going forward next week. we need to stay above with the trend and break through those supports. main one is .18 for some reason, once that it gone then it is off to the races!
intersing levels in this trade with a nice weekly for reversal lets see sl under 14 strong support 10 centss targets posted in the chart
This Long position is from Monday at 9:30 am at which my group is holding positions at $0.16 We are planning to buy as many shares in the red zone and hold. Regardless if price does not reach $0.40 by Friday at 9:30 am. We are still going to hold this stock in our portfolio for a minimum of 3 quarters. The goal here is patience and steady growth. We look to see...
SELLAS intends to use the net proceeds from the offering to commence a pivotal Phase 3 trial for its lead clinical candidate, galinpepimut-S (“GPS”), as a monotherapy in acute myeloid leukemia patients following second complete remission and to continue its Phase 1/2 basket type trial of GPS in combination with pembrolizumab, as well as for general corporate...
POSITIVE DATA RELEASED ON PHASE SELLAS AnnounceS Response Data in Triple Negative Breast Cancer Patients from Phase 2b Study of Nelipepimut-S. KEEP ON WATCH FOR SOME VERY POSITIVE MOVES. SHORT INTEREST 13.2% AVERAGE ANALYSTS PRICE TARGET $8.75 AVERAGE ANALYSTS RECOMMENDATION OVERWEIGHT COMPANY PROFILE SELLAS is a clinical-stage biopharmaceutical company...